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Environmental exposure to lead (Pb) early in life results in a latent upregulation of genes and products
associated with Alzheimer’s disease (AD), particularly the plaque forming protein amyloid beta (Ab).
Furthermore, animals exposed to Pb as infants develop cognitive decline and memory impairments in
old age. Studies from our lab demonstrated that tolfenamic acid lowers the levels of the amyloid b
precursor protein (APP) and its aggregative cleavage product Ab by inducing the degradation of the
transcription factor speciﬁcity protein 1 (Sp1). These changes were accompanied by cognitive
improvement in transgenic APP knock-in mice. In this study, we examined the effects of tolfenamic acid
on beta site APP cleaving enzyme 1 (BACE1) which is responsible for Ab production and tested its ability
to reverse Pb-induced upregulation in the amyloidogenic pathway. Mice were administered tolfenamic
acid for one month and BACE1 gene expression as well as its enzymatic activity were analyzed in the
cerebral cortex. Tolfenamic acid was also tested for its ability to reverse changes in Sp1, APP and Ab that
were upregulated by Pb in vitro. Differentiated SH-SY5Y neuroblastoma cells were either left unexposed,
or sequentially exposed to Pb followed by tolfenamic acid. Our results show that tolfenamic acid reduced
BACE1 gene expression and enzyme activity in mice. In neuroblastoma cells, Pb upregulated Sp1, APP and
Ab, while tolfenamic acid lowered their expression. These results along with previous data from our lab
provide evidence that tolfenamic acid, a drug that has been used for decades for migraine, represents a
candidate which can reduce the pathology of AD and may mitigate the damage of environmental risk
factors associated with this disease.
 2014 Elsevier Ltd. All rights reserved.1. Introduction
A century has passed since the disease was ﬁrst described by
Alois Alzheimer and about 35 million patients around the world
suffer today from Alzheimer’s disease (AD) without any potential
cure (Anstey et al., 2013; Selkoe, 2012). Themajority of AD cases are
sporadic and the exact causes of the disease are unknown. As no
means for prevention are available, the number of AD cases and the
enormous economic costs of this devastating disease will continue
to grow at an alarming rate. Knowledge on the pathophysiology of
the disease continues to be gathered and reveal more possible drugdisease; ANOVA, analysis of
ta-site APP cleaving enzyme;
of the mean; Sp1, speciﬁcity
osome.
nd, Neurodegeneration and
, RI 02881, USA. Tel.: þ1 401
All rights reserved.targets and disease biomarkers. Two types of deposits are found in
the AD brain, the amyloid plaques and the tau neuroﬁbrillary tan-
gles (Terry et al., 1964; Tomlinson, 1982). A lot of attention has been
directed to the plaques and their main constituent amyloid beta
(Ab) as well as intermediates in Ab production or degradation,
especially after the development of the amyloid cascade hypothesis
which views Ab as a major trigger in AD pathology (Hardy and
Selkoe, 2002; Hardy and Higgins, 1992). However, so far no
disease-modifying drug for AD is available.
Ab is generated following the sequential enzymatic processing
of the amyloid b precursor protein (APP) by b-secretase and g-
secretase (Shoji et al., 1992). The produced Ab is normally secreted,
but also can accumulate and form insoluble aggregates (Shoji et al.,
1992; Urbanc et al., 1999). The levels and activity of b-secretase are
elevated in AD brains compared to control (Holsinger et al., 2002; Li
et al., 2004). b-APP cleaving enzyme 1 (BACE1) is the main form of
b-secretase that cleaves APP to generate Ab (Cai et al., 2001). In an
alternative pathway for processing APP, it can be cleaved by the
enzyme a-secretase within the Ab fragment resulting in non-
amyloidogenic products (Selkoe, 1994). Ab is found as 36e43
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Ab42 is the most aggregative and is proposed to trigger plaque
formation in AD (Iwatsubo et al., 1994; Nakano et al., 1999; Naslund
et al., 2000).
Speciﬁcity protein 1 (Sp1) is a transcription factor that has been
associated with the pathology of AD (Basha et al., 2005; Santpere
et al., 2006; Zawia and Basha, 2005). Sp1 acts as a co-activator of
APP transcription and regulates the expression of BACE1
(Christensen et al., 2004; Docagne et al., 2004). Sp1 regulates gene
transcription by binding to GC rich promoter regions in genes like
APP and BACE1 whose binding to Sp1 increases their transcription
(Christensen et al., 2004; Docagne et al., 2004; Hoffman and
Chernak, 1995; Pollwein et al., 1992). Overexpression of Sp1 in-
creases BACE1 promoter activity, while the decline in Sp1 reduces
BACE1 gene transcription (Christensen et al., 2004). Immunohis-
tochemical studies from our laboratory demonstrated that Sp1
protein (SP1), APP, and Ab co-localize in brain neurons, and that
cortical and hippocampal areas with higher SP1 levels express
more Ab (Brock et al., 2008). Therefore, changes in Sp1 expression
can inﬂuence APP and BACE1 transcription and consequently alter
the levels of their downstream product Ab. Sp1 represents a po-
tential AD target, where its abnormal and elevated expression has
been associated with the disease decline (Brock et al., 2008;
Christensen et al., 2004; Citron et al., 2008; Hoffman and
Chernak, 1995; Santpere et al., 2006; Zawia and Basha, 2005).
Exposure to the environmental toxicant lead (Pb) is considered a
risk factor with detrimental effects on various organs especially the
brain (White et al., 2007; Zawia and Basha, 2005; Zawia et al.,
2009). Experiments conducted at our lab demonstrated that Pb
exposure early in life results in AD like pathology in vitro and
in vivo, in rodents and primates (Basha et al., 2005;Wu et al., 2008).
Pb administration caused the upregulation of Sp1, APP, Ab, BACE1
and other intermediates implicated in AD later in life (Basha et al.,Fig. 1. Downregulation of BACE1 and APP by tolfenamic acid and their upregulation by early
which reduces the transcription of APP and BACE1, consequently reducing the expression of
On the other hand, studies from our lab have revealed that Pb exposure early in life upregula
solid arrows represent the hypothetical consequences following tolfenamic acid exposure,2005; Bihaqi et al., 2013, 2011; Bihaqi and Zawia, 2012; Huang et al.,
2011; Wu et al., 2008; Zawia et al., 2009). Our most recent studies
revealed that these molecular changes were accompanied by
cognitive deterioration in mice administered Pb compared to con-
trols (Bihaqi et al., 2013). On the other hand, studies in our lab also
showed that promoting SP1 degradation by oral administration of
the anti-migraine drug tolfenamic acid to mice reduces APP and Ab
levels as well as improves cognition (Adwan et al., 2011; Subaiea
et al., 2013).
Since the transcription factor Sp1 is vital for the regulation of
several genes involved in AD including BACE1, this research study
was conducted to assess the effect of tolfenamic acid administra-
tion to APP yeast artiﬁcial chromosome (YAC) transgenic mice on
BACE1, as a major enzyme in the production of Ab, that is under Sp1
regulation. We also utilized an in vitro model of Pb exposure
established in our lab to test the ability of tolfenamic acid to rescue
proteins upregulated following Pb exposure, which induces mo-
lecular consequences that resemble pathological events observed
in late onset AD (Bihaqi and Zawia, 2012; Huang et al., 2011).
Following cell viability studies, differentiated SH-SY5Y cells were
exposed to Pb, tolfenamic acid or both agents in chronological order
and the changes on SP1, APP and Abwere examined in comparison
to control. An illustration of the mechanism of action of tolfenamic
acid induced APP and BACE1 reduction can be found in Fig. 1.
2. Materials and methods
2.1. Animals
Female hemizygous APP YAC transgenic mice (line R1.40) were used in this
study. The B6.129-Tg(APPSw)40Btla/Mmjax strain was obtained from the Jackson
Laboratory, Bar Harbor, ME. Animals were bred in-house and the age of the mice
used in this study was between 14 and 20 months. This AD animal model contains
the entire human APP gene including the regulatory fragments and expresses
elevated levels of Ab especially the longer more aggregative forms Ab42 and Ab43
(Lamb et al., 1999, 1997; Lehman et al., 2003). Animals were housed in designatedPb exposure. Tolfenamic acid stimulates the degradation of the transcription factor Sp1,
BACE1 and APP as well as the aggregative product Ab and the associated AD pathology.
tes the expression of Sp1, APP, BACE1, Ab and induces AD like pathology later in life. The
whereas the hollow arrows represent the latent effects after Pb exposure.
Fig. 2. BACE1 relative gene expression within the cerebral cortices of R1.40 transgenic
mice following tolfenamic acid exposure. Hemizygous transgenic APP YAC mice were
administered 0, 5 or 50 mg/kg/day tolfenamic acid for 34 days. BACE1 mRNA levels
were measured in the cerebral cortex by real time PCR with b-actin as endogenous
control as illustrated in the methods section. Values shown are the mean  SEM, n ¼ 5
in each group, p ¼ 0.0116 as determined by one-way ANOVAwith TukeyeKramer post-
test *p < 0.05.
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conditions with ad libitum food andwater. All efforts weremade tominimize animal
suffering, to reduce the number of animals used, and to utilize alternatives to in vivo
techniques, if available. Mice were assigned into 3 groups of similar age variations,
n ¼ 6 in each group. Animals were administered 0, 5 or 50 mg/kg tolfenamic acid
(Sigma-Aldrich, St. Louis, MO) in corn oil every day by oral gavage for 34 days. On day
35, mice were sacriﬁced and brain tissues were collected and stored at 80 C until
further use. All experiments were performed in accordance with the standard
guidelines and the protocol approved by the Institutional Animal Care and Use
Committee of the University of Rhode Island.
2.2. Cell culture and exposure to Pb and tolfenamic acid
Human neuroblastoma SH-SY5Y cells were purchased from American Type
Culture Collection (ATCC, Manassas, VA). Cells were maintained in Dulbecco’s
Modiﬁed Eagle Medium (DMEM)/F12 (Life technologies, Grand Island, NY) with 10%
fetal bovine serum (FBS) and 100 U/mL penicillin,100 mg/mL streptomycin and 2mM
L-glutamine at 5% CO2 and 37 C. Cells were subcultured at 105 cells/mL in ﬂasks
containing 10 mL each and were allowed to attach overnight then they were
differentiated in 10 mM all-trans retinoic acid (SigmaeAldrich, St. Louis, MO) in
DMEM/F12 containing 1% FBS and 100 U/mL penicillin, 100 mg/mL streptomycin and
2mM L-glutamine for 1 week following previously published methods (Huang et al.,
2011; Jamsa et al., 2004). Neurite outgrowth was examined at 48, 72 h and 6 days
(Jamsa et al., 2004) and the medium was changed every 48 h. Following differen-
tiation, cells were exposed to Pb, tolfenamic acid or both sequentially. Stock solu-
tions of 10 mM Pb acetate in sterile distilled water and 100 mM tolfenamic acid in
DMSOwere prepared for treatments. The stock solutions were diluted in DMEM/F12
media containing 1% FBS, 100 U/mL penicillin, 100 mg/mL streptomycin and 2 mM L-
glutamine for the different exposures. The concentration of DMSO in the cell culture
media was maintained at 0.05% for control or treatments. Differentiated SH-SY5Y
cells were treated with 0 or 25 mM tolfenamic acid for 96 h with the media
changed every 48 h. Cells were also exposed to 50 mM Pb for 48 h after which the
media was removed and replaced with media containing 0, 25 or 50 mM tolfenamic
acid for another 48 h. Cells exposed to media containing 0.05% DMSO,1% FBS, 100 U/
mL penicillin, 100 mg/mL streptomycin and 2 mM L-glutamine with no Pb or tolfe-
namic acid were used as controls.
2.3. Cell viability assay
SH-SY5Y cells were loaded at 104 cells per 100 mL in each well onto 96-well
plates and were allowed to attach overnight then were differentiated using
100 mM all-trans retinoic acid. Differentiated cells were exposed to 0, 1, 2.5, 5, 10, 50,
or 100 mM tolfenamic acid for 12, 24, or 72 h with six replicates per group. Cells were
incubated at 37 C with 5% CO2 and 90% humidity. Cell viability was determined
using the Vybrant MTT cell proliferation assay kit following the manufacturer’s
instructions (Life technologies, Grand Island, NY). Absorbance at 570 nm was
measured using Spectra Max UV/Vis Spectrometer (GMI, Ramsey, MN) and cell
viability was determined in treatment groups as a percentage from control.
2.4. RNA isolation, cDNA synthesis and real time PCR
RNA was isolated from cerebral cortex tissue following the TRIzol Reagent
method (Invitrogen, Carlsbad, CA), checked for integrity by NanoDrop (Thermo
Scientiﬁc, Wilmington, DE), and reverse transcribed to cDNA using iScript Select
cDNA Synthesis kit following manufacturer’s instructions (Bio-Rad, Hercules, CA).
About 1000 ng of RNA were diluted to 19.5 mL with nuclease free water, then 3 mL
Oligo (dT) mix, 6 mL 5 iScript Select reaction mix, and 1.5 mL of iScript reverse
transcriptase were added. Samples were incubated at 42 C for 90 min then at 85 C
for 5 min to terminate the reaction. All incubations were conducted using MJ
Research MiniCycler (Bio-Rad, Hercules, CA). Primer pairs for mouse BACE1 or b-
actin and human APP or GAPDH were obtained from Invitrogen (Carlsbad, CA) as
follows: BACE1 sense: 50-ATG TGC ACG ATG AGT TCA GG-30 and antisense: 50-GCA
GAG TGG CAA CAT GAA GA-30; b-actin sense: 50-TGT TAC CAA CTG GGA CGA CA-30 ,
and antisense: 50-TCT CAG CTG TGG TGG TGA AG-30; APP sense: 50-GCC AAA GAG
ACA TGC AGT GA-30 and antisense: 50-CCA GAC ATC CGA GTC ATC CT-30; GAPDH
sense: 50-AGC TGA ACG GGA AGC TCACT-30 , and antisense: 50-AGG TCC ACC ACT GAC
ACG TTG-30 . Each real time PCR reaction mix contained 2 mL of cDNA, 1 mL of each
primer, 8.5 mL nuclease freewater and 12.5 mL SYBRGreen PCRMasterMix (Applied
Biosystems, Foster City, CA). Real time PCR was conducted using the 7500 Real Time
PCR System (Applied Biosystems, Foster City, CA) following the standard protocol:
50 C for 2 min followed by 95 C for 10 min, then 40 cycles of 95 C for 15 s and
60 C for 1 min. Results were analyzed using the 7500 system software with relative
quantiﬁcation method and b-actin as endogenous control.
2.5. Protein extraction and Western blot analyses
Cytoplasmic and nuclear extractions from neuroblastoma cells were carried out
using NE-PER nuclear and cytoplasmic extraction reagents according to the manu-
facturer’s instructions (Thermo Scientiﬁc Pierce, Rockford, IL). Protein concentration
was determined using the Micro BCA Protein Assay Kit (Thermo Scientiﬁc Pierce,
Rockford, IL). Protein extracts were stored at 80 C until further use. Samplescontaining 20 mg nuclear proteinwere separated onto 4e15% precast polyacrylamide
gels (Bio-Rad, Hercules, CA) at 150 V for 1e2 h and then transferred to PVDF
membranes (GE-Healthcare, Piscataway, NJ). Membranes were blocked and incu-
bated with the appropriate dilution of the speciﬁc primary antibody for 1e2 h;
either 1:500 dilution of ABE135 for SP1 levels (Millipore, Billerica, MA) or 1:2000 of
GAPDH T9450 (SigmaeAldrich, St. Louis, MO) were used. Then the membranes were
washed with TBST four times and incubated with the appropriate infrared dye-
labeled secondary antibody (Li-Cor, Lincoln, NE) for 1 h at room temperature in
the dark. Infrared signal of Western blot bands was detected and quantiﬁed using an
Odyssey Infrared Imaging System (Li-Cor, Lincoln, NE). Western blot bands were
normalized against the levels of the house keeping protein GAPDH.
2.6. BACE1 activity assay
BACE1 activity within the cerebral cortices of control and treated mice was
measured using SensiZyme BACE1 activity assay kit CS1060 (SigmaeAldrich, St.
Louis, MO) following the manufacturer’s instructions. Brieﬂy 100 mL of blank,
standards, or samples containing 450 mg protein were loaded into wells pre-coated
with anti-BACE1 antibody. Samples were incubated for 2 h at 4 C, after that, wells
were washed 4 times then 50 mL of BACE1 substrate A was added to each well and
incubated overnight at room temperature in a humidiﬁed chamber. On the next day,
50 mL of the colorimetric substrate B reagent mixture was added to the wells and
incubated at room temperature for 3 h. At the end of the incubation period,
absorbance was measured at 405 nm using Spectra Max UV/Vis Spectrometer (GMI,
Ramsey, MN) and BACE1 activity was calculated in ng/mL using the standard curve.
2.7. ELISA Ab40 assay
Levels of Ab40 in cell culture media were measured using human Ab40 kit
JP27713 (IBL, Gunma, Japan). The kit is solid-phase sandwich ELISA with a highly
speciﬁc antibody that is 100% reactivewith human Ab40 with a sensitivity of 5.00 pg/
mL. The kit measures Ab40 cleaved N-terminal side by any cause. The assay was
conducted following manufacturer’s instructions with minor modiﬁcations. One
hundred mg protein as determined byMicro BCA protein assay kit (Thermo Scientiﬁc
Pierce, Rockford, IL) in 100 mL EIA buffer and assay standards were added in tripli-
cates to 96-well plates pre-coated with anti-human Abmouse IgG MoAb. The plates
were incubated overnight at 4 C, and washed 7 times using the 40 diluted wash
buffer supplied with the kit (0.05% Tween 20 in phosphate buffer), and 100 mL
labeled antibody was added and incubated for 1 h at 4 C, the wells were washed
again 9 times, and then 100 mL of tetramethylbenzidine was added as a coloring
agent, and incubated in the dark for 30 min at room temperature. Finally 100 mL of
1 N H2SO4 was added to stop the reaction, and absorbance was measured at 450 nm
using Spectra Max UV/Vis spectrometer (GMI, Ramsey, MN). The concentration of
Ab40 in unknown samples was calculated as pg/mg total protein using the standard
curve obtained.
2.8. Statistical analysis
Data was represented as the mean  the standard error of the mean (SEM).
Statistical analysis was performed using GraphPad Instat software (GraphPad soft-
ware, San Diego, CA) and statistical signiﬁcance was determined by one-way anal-
ysis of variance (ANOVA) and TukeyeKramer multiple comparisons post-test.
Results with p-values <0.05 were considered signiﬁcantly different from the group
in comparison and were marked accordingly.
Fig. 4. Cell viability of differentiated SH-SY5Y cells following tolfenamic acid exposure.
Neuroblastoma cells were differentiated and exposed to media containing 0, 1, 2.5, 5,
10, 25, 50 or 100 mM tolfenamic acid for 12 h, 24 h, or 72 h and cell viability was
studied using MTT as illustrated in the methods section. Values shown are the
mean  SEM, n ¼ 6 in each group, overall one-way ANOVA p < 0.0001, one-way
ANOVA p ¼ 0.8164 for groups in the 12 h exposure; p < 0.0001 for groups in the
24 h; and p < 0.0001 for groups in the 72 h exposure. ***p < 0.001 compared to the
corresponding control group from the same time duration of exposure as determined
by TukeyeKramer post-test.
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Tolfenamic acid has been used for years in humans for migraine
headaches and rheumatoid arthritis. In our experiments, tolfe-
namic acid was well tolerated by the animals and no side effects
were observed. Data obtained by our collaborators at M. D.
Anderson Cancer Center also found that chronic administration of
tolfenamic acid was not toxic and had no adverse effects on ani-
mals’ weight, hematocrit, stomach or intestinal lining integrity
compared to control (Sankpal et al., 2013).
3.1. Tolfenamic acid lowers BACE1 gene expression in vivo
Following the administration of tolfenamic acid to APP YAC
transgenic mice daily for 34 days, BACE1 gene expression within
the cerebral cortex was lowered by 30% with both the 5 and 50 mg/
kg doses as determined by real time PCR (Fig. 2). One-way ANOVA
F(2,12) ¼ 6.614, p ¼ 0.0116, TukeyeKramer multiple comparisons
post-test p < 0.05 for the control vs 5 mg/kg group and for control
vs 50 mg/kg group.
3.2. Tolfenamic acid reduces BACE1 activity
The activity of the enzyme BACE1 in the cerebral cortex was
examined following the exposure of APP YAC transgenic mice to
tolfenamic acid for 34 days. BACE1 enzyme activity was reduced by
45% with the 5 and 50 mg/kg/day doses as determined by One-way
ANOVA (F(2,12) ¼ 5.547, p ¼ 0.0197), TukeyeKramer multiple
comparisons post-test p < 0.05 for the control vs 5 mg/kg and for C
vs 50 mg/kg group (Fig. 3).
3.3. Tolfenamic acid cell viability studies in differentiated
neuroblastoma cells
The viability of SH-SY5Y cells differentiated using all-trans ret-
inoic acid was examined following treatments with 0e100 mM
tolfenamic acid. The results show that tolfenamic acid did not cause
any cytotoxicity until the highest dose of 100 mMafter 24 h and 72 h
of exposure (p < 0.001) (Fig. 4). This suggests that the effects of
tolfenamic acid on cell viability are time and dose-dependent.
Overall one-way ANOVA reported a p-value less than 0.0001;
one-way ANOVA p ¼ 0.8164 for groups in the 12 h exposure;
p < 0.0001 for the 24 h treatment groups; and p < 0.0001 for
groups in the 72 h exposure. Based on these results, we chose the
doses of 25 and 50 mMof tolfenamic acid for the following exposure
experiments in neuroblastoma cells.Fig. 3. BACE1 enzyme activity in the cerebral cortex of APP YAC transgenic mice
following tolfenamic acid exposure. BACE1 activity was measured using SensiZyme
BACE1 activity assay kit from SigmaeAldrich as illustrated in the methods section.
Values shown are the mean  SEM, n ¼ 5. One-way ANOVA p ¼ 0.0197 *p < 0.05 as
determined by TukeyeKramer post-test.3.4. Tolfenamic acid lowers SP1 in vitro
Exposure of differentiated SH-SY5Y cells to 50 mM Pb for 48 h
followed by Pb-free media for 48 h induced the expression of SP1
by 47% which did not reach statistical signiﬁcance according to
TukeyeKramer post-test when compared to control. However,
when Pb treatment for 48 h was succeeded by exposure to 25 mM
tolfenamic acid for 48 h, SP1 levels were decreased by 75%
compared to control which was deemed statistically signiﬁcant
according to TukeyeKramer post-test (p < 0.05), and by 83% when
compared to SP1 levels in cells exposed to Pb for 48 h followed by
Pb-free media for 48 h (p< 0.01). Overall one-way ANOVA between
all groups reported a p-value equal to 0.003, F(2,5)¼ 22.093 (Fig. 5).3.5. Effects of tolfenamic exposure on APP gene expression
Treatment of cells with tolfenamic acid for 96 h reduced the
gene expression of APP compared to control by 18% that was not
statistically signiﬁcant. Whereas the exposure of cells to Pb for 48 h
followed by Pb-free media for 48 h increased APP gene expression
by 23% which did not reach statistical signiﬁcance when compared
to control. Tolfenamic acid treatment after Pb lowered the Pb-
induced APP gene expression in differentiated neuroblastoma
cells by 60% from control (p < 0.05) and by 67% from cells exposed
to Pb for 48 h followed by Pb-free media for 48 h (p< 0.01). Overall
one-way ANOVA reported a p-value of 0.001, F(4,21) ¼ 6.905
(Fig. 6).3.6. Tolfenamic acid lowers the levels of Ab40 induced by Pb
Ab levels were increased by 42% in differentiated SH-SY5Y cells
after treatment with Pb for 48 h followed by Pb-free media for
additional 48 h (Fig. 7). This increase was signiﬁcant when
compared to cells maintained in Pb-free media for 96 h with the
media changed every 48 h according to TukeyeKramer multiple
comparison test (p< 0.01). When treatment of SH-SY-5Y cells by Pb
for 48 h was followed by treatment with 25 mM tolfenamic acid for
48 h, there was a trend of reduction in Ab levels in the media by 10%
compared to treatment with Pb for 48 h followed by Pb-free media
for 48 h. Ab levels were decreased by 56% with the 50 mM tolfe-
namic acid concentration for 48 h following prior Pb exposure for
48 h which was signiﬁcant compared to Ab levels in the media of
Fig. 5. SP1 levels in differentiated SH-SY5Y cells after treatment with Pb followed by
Pb-free media or by tolfenamic acid. SH-SY5Y cells were differentiated using 100 mM
all-trans retinoic acid and where either unexposed (control, C) for 96 h with the media
changed every 48 h, or exposed to 50 mM Pb for 48 h followed by 0 or 25 mM tolfenamic
acid (TA) for 48 h. Values shown are the mean  SEM. Three independent experiments
were performed in triplicates. SP1 levels were normalized to the levels of the house
keeping protein GAPDH. One-way ANOVA p ¼ 0.003, with TukeyeKramer post-test
*p < 0.05 compared to C, yyp < 0.01 compared to 48 h Pb followed by 48 h Pb-free
media exposure group. Insert shows representative SP1 and GAPDH Western blot
bands from 96 h control (C); 48 h Pb treatment followed by 48 h Pb-free media; or 48 h
Pb exposure followed by 48 h tolfenamic acid (TA) treatment.
Fig. 7. Ab levels in differentiated SH-SY5Y cells exposed to tolfenamic acid, Pb or both.
Differentiated neuroblastoma cells were either left unexposed (control, C) or were
exposed to 25 mM tolfenamic acid (TA) for 96 h with the media changed every 48 h; or
50 mM Pb for 48 h followed by either 0, 25, or 50 mM tolfenamic acid for 48 h. Ab levels
within the media were measured using ELISA as explained in the methods section.
Overall one-way ANOVA revealed p < 0.0001 between all groups. TukeyeKramer post-
test *p < 0.05 compared to 25 mM TA group; þp < 0.05, þþp < 0.01 compared to C
group and 25 mM TA group; yyyp < 0.001 compared to 48 h Pb followed by 48 h C group
and compared to 48 h Pb followed by 48 h 25 mM TA group.
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(p < 0.001); and Ab levels were reduced by 37% compared to
control (p < 0.05). However, treatment of cells with 25 mM tolfe-
namic acid for 96 h did not change Ab levels within the media. The
overall one-way ANOVA p-value between groups was p < 0.0001,
F(4,12) ¼ 22.537 (Fig. 7).4. Discussion
Up to now, ﬁve drugs that belong to two classes have been
approved for AD, the cholinesterase inhibitors and the NMDA re-
ceptor antagonist memantine. These interventions aim at
improving memory functions to some extent but do not stop the
dementia and the ultimate loss of daily functioning caused by AD.Fig. 6. APP gene expression in differentiated SH-SY5Y cells exposed to tolfenamic acid,
Pb or both. Differentiated neuroblastoma were exposed to 25 mM tolfenamic acid (TA)
for 96 h with the media changed every 48 h; cells were also exposed to 50 mM Pb for
48 h followed by 0, 25 or 50 mM tolfenamic acid for 48 h; ﬁnally, cells were left un-
exposed (Control, C). APP gene expression was measured by real time PCR with GAPDH
as endogenous control as illustrated in the methods section. One-way ANOVA
p ¼ 0.001. TukeyeKramer post-test *p < 0.05 compared to C, yyp < 0.01 compared to
48 h Pb followed by 48 h C exposure group.Many other candidates were in preclinical and clinical trials but
failed to demonstrate safety or efﬁcacy. Several AD targets under
investigation are within the amyloid pathway of AD including APP,
b-secretase, g-secretase and Ab itself. Yet, no successful candidate
that can change the course of AD has been found.
Research studies including those conducted in our lab demon-
strate that the transcription factor Sp1 is involved in AD pathology
(Brock et al., 2008; Christensen et al., 2004; Citron et al., 2008;
Docagne et al., 2004; Santpere et al., 2006). Sp1 regulates the
expression of APP, BACE1 and tau (Christensen et al., 2004; Docagne
et al., 2004; Heicklen-Klein and Ginzburg, 2000; Hoffman and
Chernak, 1995). SP1 co-localizes with APP and Ab in brain neurons
as well as with tau in tangles (Brock et al., 2008; Santpere et al.,
2006). Due to its unique role in the transcription of AD related
genes, targeting Sp1 is a novel and promising approach for
discovering disease-modifying drugs for AD. Ab and other factors
involved in its processing are being targeted for AD. Vaccines
against Ab are under development although several have failed in
clinical trials due to life threatening adverse effects such as
meningoencephalitis (Delrieu et al., 2012; Schnabel, 2011). The
structural properties of the BACE active site limit the chances for
development of inhibitors for this enzyme (Tamagno et al., 2012).
Whereas g-secretase inhibitors have failed due to toxicity associ-
ated with the inhibition of the Notch signaling (Mattson, 2004;
Ross and Imbimbo, 2010).
Our previous work demonstrated that tolfenamic acid was able
to downregulate proteins implicated in AD pathology including
APP and Ab (Adwan et al., 2011; Subaiea et al., 2013). In this study,
we conﬁrmed that tolfenamic acid also lowers BACE1, another
protein that is regulated by Sp1 and takes part in the amyloidogenic
pathway of AD (Christensen et al., 2004). Following tolfenamic acid
daily administration for about 1 month, the gene expression and
activity of BACE1 were reduced in APP YAC transgenic mice (Figs. 2
and 3). In these animals, tolfenamic acid also lowered SP1, APP and
Ab as well as improved cognition as determined by behavioral tests
using the Morris water maze and the Y-maze (Subaiea et al., 2013).
The toxic effects of Pb on health have been described in the
literature, experiments from our lab showed that Pb induced the
expression of AD related genes and proteins including Sp1, APP, Ab,
and tau (Basha et al., 2005; Bihaqi and Zawia, 2012; Huang et al.,
L. Adwan et al. / Neuropharmacology 79 (2014) 596e602 6012011; Wu et al., 2008). BACE1 gene expression and activity were
also increased following early Pb exposure in mice (Bihaqi et al.,
2013). Hence, tolfenamic acid and Pb represent two agents that
have opposing effects when it comes to AD related pathways.
The safety of tolfenamic acid has already been established and
the drug has been used for migraine headaches in Europe for de-
cades (Hakkarainen et al., 1982, 1979; Myllyla et al., 1998; Tokola
et al., 1984). In our studies, no signs of toxicity were observed
throughout the exposure periods. In neuroblastoma cells, lower
doses of tolfenamic acid did not affect cell viability (Fig. 4). A
decrease in cell viability with tolfenamic acid was observed at the
higher concentration of 100 mM and at the longer periods of
exposure of 24 h and 72 h. The outcomes of tolfenamic acid on cell
viability were dose and time dependent.
To study the effects of tolfenamic acid on AD related genes and
proteins in neuroblastoma cells, we chose the 25 and 50 mM
concentrations which did not affect cell viability based on our
results. The 50 mM dose chosen for Pb exposure came from our
previous cell viability and exposure studies with the same cell line
(Bihaqi and Zawia, 2012; Huang et al., 2011). Our results show that
the exposure of differentiated SH-SY5Y neuroblastoma cells to
tolfenamic acid for 48 h after 48 h of Pb exposure decreased SP1
levels signiﬁcantly compared to control or cells exposed to Pb
followed by Pb-free media for 48 h each (Fig. 5). Furthermore,
tolfenamic acid signiﬁcantly reduced APP gene and Ab expression
that was induced by Pb exposure but not the basal levels of APP
and Ab (Figs. 6 and 7).
The 25 mM dose of tolfenamic acid was able to decrease SP1
levels and APP gene expression induced by prior Pb exposure.
However, Ab levels were only decreased signiﬁcantly by the 50 mM
tolfenamic acid exposure after Pb. As tolfenamic acid affects tran-
scription, time is an important factor for observing its effects and in
this study, although the 25 mM tolfenamic acid was very effective in
lowering SP1 and APP gene expression following Pb administration,
this drastic change was not translated into Ab lowering probably
due to insufﬁcient time for effects on Ab to show. For example, our
previous studies showed that even though APP gene transcription
was lowered following tolfenamic acid daily administration in mice
for three days, APP protein levels were not lowered at that time
(Adwan et al., 2011). Whereas the levels of both APP gene and
protein were decreased after two weeks of tolfenamic acid daily
administration to mice (Adwan et al., 2011).
About 90% of AD cases are sporadic and are referred to as late
onset AD with age being the major risk factor (Alzheimer’s
Association, 2012). Our lab has demonstrated that early Pb expo-
sure replicates pathological events observed late in life in ADwithin
various in vitro and in vivo models (Basha et al., 2005; Bihaqi et al.,
2011; Bihaqi and Zawia, 2012; Huang et al., 2011; Wu et al., 2008).
In this manuscript, we use prior Pb exposure as a model that causes
upregulation of AD related intermediates including APP and Ab by
inducing the transcription factor Sp1, in amatter that resembles the
environmentally inﬂicted late onset AD. After Pb exposure, we
exposed the cells to tolfenamic acid, in order to test its ability to
reverse the events caused by Pb. Our results show that tolfenamic
acid was able to rescue the cells from the pathological increase in
SP1, APP and Ab.
Tolfenamic acid is a multi-target drug candidate for AD that
mitigates the amyloid pathology of AD. By decreasing Sp1, tolfe-
namic acid was able to lower BACE1 expression and activity in vivo
and to alleviate changes in APP and Ab in vitro. The safety of tol-
fenamic acid use in humans has already been established as it has
been approved and used for years in Europe for migraine head-
aches. Hence it represents a promising agent that can be repur-
posed for AD and was recently scheduled to be tested in AD
patients.Acknowledgements
This research was supported by the Intramural Research Pro-
gram of the National Institutes of Health (NIH), National Institute of
Environmental Health Sciences (NIEHS) and by grants NIH e
ES015867 and AG042695 awarded to NHZ. The research was sup-
ported by an Institutional Development Award (IDeA) from the
National Institute of General Medical Sciences of the National In-
stitutes of Health under grant number 8 P20 GM103430-12.References
Adwan, L.I., Basha, R., Abdelrahim, M., Subaiea, G.M., Zawia, N.H., 2011. Tolfenamic
acid interrupts the de novo synthesis of the beta-amyloid precursor protein and
lowers amyloid beta via a transcriptional pathway. Curr. Alzheimer Res. 8, 385e
392.
Alzheimer’s Association, 2012. 2012 Alzheimer’s disease facts and ﬁgures. Alz-
heimers Dement. 8, 131e168.
Anstey, K.J., Cherbuin, N., Herath, P.M., 2013. Development of a new method for
assessing global risk of Alzheimer’s disease for use in population health ap-
proaches to prevention. Prev. Sci. 14 (4), 411e421.
Basha, M.R., Wei, W., Bakheet, S.A., Benitez, N., Siddiqi, H.K., Ge, Y.W., Lahiri, D.K.,
Zawia, N.H., 2005. The fetal basis of amyloidogenesis: exposure to lead and
latent overexpression of amyloid precursor protein and beta-amyloid in the
aging brain. J. Neurosci. 25, 823e829.
Bihaqi, S.W., Bahmani, A., Subaiea, G.M., Zawia, N.H., 2013. Infantile exposure to lead
and late-age cognitive decline: relevance to AD. Alzheimers Dement..
Bihaqi, S.W., Huang, H., Wu, J., Zawia, N.H., 2011. Infant exposure to lead (Pb) and
epigenetic modiﬁcations in the aging primate brain: implications for Alz-
heimer’s disease. J. Alzheimers Dis. 27, 819e833.
Bihaqi, S.W., Zawia, N.H., 2012. Alzheimer’s disease biomarkers and epigenetic in-
termediates following exposure to Pb in vitro. Curr. Alzheimer Res. 9, 555e562.
Brock, B., Basha, R., DiPalma, K., Anderson, A., Harry, G.J., Rice, D.C., Maloney, B.,
Lahiri, D.K., Zawia, N.H., 2008. Co-localization and distribution of cerebral APP
and SP1 and its relationship to amyloidogenesis. J. Alzheimers Dis. 13, 71e80.
Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D.R., Price, D.L., Wong, P.C., 2001.
BACE1 is the major beta-secretase for generation of Abeta peptides by neurons.
Nat. Neurosci. 4, 233e234.
Christensen, M.A., Zhou, W., Qing, H., Lehman, A., Philipsen, S., Song, W., 2004.
Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-
secretase, by Sp1. Mol. Cell. Biol. 24, 865e874.
Citron, B., Dennis, J., Zeitlin, R., Echeverria, V., 2008. Transcription factor Sp1 dys-
regulation in Alzheimer’s disease. J. Neurosci. Res. 86, 2499e2504.
Delrieu, J., Ousset, P.J., Caillaud, C., Vellas, B., 2012. ‘Clinical trials in Alzheimer’s
disease’: immunotherapy approaches. J. Neurochem. 120 (Suppl. 1), 186e193.
Docagne, F., Gabriel, C., Lebeurrier, N., Lesne, S., Hommet, Y., Plawinski, L.,
Mackenzie, E.T., Vivien, D., 2004. Sp1 and Smad transcription factors co-operate
to mediate TGF-beta-dependent activation of amyloid-beta precursor protein
gene transcription. Biochem. J. 383, 393e399.
Hakkarainen, H., Parantainen, J., Gothoni, G., Vapaatalo, H., 1982. Tolfenamic acid
and caffeine: a useful combination in migraine. Cephalalgia Int. J. Headache 2,
173e177.
Hakkarainen, H., Vapaatalo, H., Gothoni, G., Parantainen, J., 1979. Tolfenamic acid is
as effective as ergotamine during migraine attacks. Lancet 2, 326e328.
Hardy, J., Selkoe, D.J., 2002. The amyloid hypothesis of Alzheimer’s disease: progress
and problems on the road to therapeutics. Science 297, 353e356.
Hardy, J.A., Higgins, G.A., 1992. Alzheimer’s disease: the amyloid cascade hypoth-
esis. Science 256, 184e185.
Heicklen-Klein, A., Ginzburg, I., 2000. Tau promoter confers neuronal speciﬁcity and
binds Sp1 and AP-2. J. Neurochem. 75, 1408e1418.
Hoffman, P.W., Chernak, J.M., 1995. DNA binding and regulatory effects of tran-
scription factors SP1 and USF at the rat amyloid precursor protein gene pro-
moter. Nucleic Acids Res. 23, 2229e2235.
Holsinger, R.M., McLean, C.A., Beyreuther, K., Masters, C.L., Evin, G., 2002. Increased
expression of the amyloid precursor beta-secretase in Alzheimer’s disease. Ann.
Neurol. 51, 783e786.
Huang, H., Bihaqi, S.W., Cui, L., Zawia, N.H., 2011. In vitro Pb exposure disturbs the
balance between Abeta production and elimination: the role of AbetaPP and
neprilysin. Neurotoxicology 32, 300e306.
Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., Ihara, Y., 1994. Visu-
alization of A beta 42(43) and A beta 40 in senile plaques with end-speciﬁc A
beta monoclonals: evidence that an initially deposited species is A beta 42(43).
Neuron 13, 45e53.
Jamsa, A., Hasslund, K., Cowburn, R.F., Backstrom, A., Vasange, M., 2004. The retinoic
acid and brain-derived neurotrophic factor differentiated SH-SY5Y cell line as a
model for Alzheimer’s disease-like tau phosphorylation. Biochem. Biophys. Res.
Commun. 319, 993e1000.
Lamb, B.T., Bardel, K.A., Kulnane, L.S., Anderson, J.J., Holtz, G., Wagner, S.L.,
Sisodia, S.S., Hoeger, E.J., 1999. Amyloid production and deposition in mutant
amyloid precursor protein and presenilin-1 yeast artiﬁcial chromosome trans-
genic mice. Nat. Neurosci. 2, 695e697.
L. Adwan et al. / Neuropharmacology 79 (2014) 596e602602Lamb, B.T., Call, L.M., Slunt, H.H., Bardel, K.A., Lawler, A.M., Eckman, C.B.,
Younkin, S.G., Holtz, G., Wagner, S.L., Price, D.L., Sisodia, S.S., Gearhart, J.D., 1997.
Altered metabolism of familial Alzheimer’s disease-linked amyloid precursor
protein variants in yeast artiﬁcial chromosome transgenic mice. Hum. Mol.
Genet. 6, 1535e1541.
Lehman, E.J., Kulnane, L.S., Lamb, B.T., 2003. Alterations in beta-amyloid production
and deposition in brain regions of two transgenic models. Neurobiol. Aging 24,
645e653.
Li, R., Lindholm, K., Yang, L.B., Yue, X., Citron, M., Yan, R., Beach, T., Sue, L.,
Sabbagh, M., Cai, H., Wong, P., Price, D., Shen, Y., 2004. Amyloid beta peptide
load is correlated with increased beta-secretase activity in sporadic Alzheimer’s
disease patients. Proc. Natl. Acad. Sci. U. S. A. 101, 3632e3637.
Mattson, M.P., 2004. Pathways towards and away from Alzheimer’s disease. Nature
430, 631e639.
Myllyla, V.V., Havanka, H., Herrala, L., Kangasniemi, P., Rautakorpi, I., Turkka, J.,
Vapaatalo, H., Eskerod, O., 1998. Tolfenamic acid rapid release versus suma-
triptan in the acute treatment of migraine: comparable effect in a double-blind,
randomized, controlled, parallel-group study. Headache 38, 201e207.
Nakano, Y., Kondoh, G., Kudo, T., Imaizumi, K., Kato, M., Miyazaki, J.I., Tohyama, M.,
Takeda, J., Takeda, M., 1999. Accumulation of murine amyloidbeta42 in a gene-
dosage-dependent manner in PS1 ‘knock-in’ mice. Eur. J. Neurosci. 11, 2577e
2581.
Naslund, J., Haroutunian, V., Mohs, R., Davis, K.L., Davies, P., Greengard, P.,
Buxbaum, J.D., 2000. Correlation between elevated levels of amyloid beta-
peptide in the brain and cognitive decline. JAMA 283, 1571e1577.
Pollwein, P., Masters, C., Beyreuther, K., 1992. The expression of the amyloid pre-
cursor protein (APP) is regulated by two GC-elements in the promoter. Nucleic
Acids Res. 20, 63e68.
Ross, J.S., Imbimbo, B.P., 2010. Are gamma-secretase inhibitors detrimental for
Alzheimer’s disease patients? J. Alzheimers Dis. 22, 401e404.
Sankpal, U.T., Lee, C.M., Connelly, S.F., Kayaleh, O., Eslin, D., Sutphin, R., Goodison, S.,
Adwan, L., Zawia, N.H., Lichtenberger, L.M., Basha, R., 2013. Cellular and
organismal toxicity of the anti-cancer small molecule, tolfenamic acid: a pre-
clinical evaluation. Cell. Physiol. Biochem. 32, 675e686.
Santpere, G., Nieto, M., Puig, B., Ferrer, I., 2006. Abnormal Sp1 transcription factor
expression in Alzheimer disease and tauopathies. Neurosci. Lett. 397, 30e34.View publication statsSchnabel, J., 2011. Vaccines: chasing the dream. Nature 475, S18eS19.
Selkoe, D.J., 1994. Cell biology of the amyloid beta-protein precursor and the
mechanism of Alzheimer’s disease. Annu Rev. Cell. Biol. 10, 373e403.
Selkoe, D.J., 2012. Preventing Alzheimer’s disease. Science 337, 1488e1492.
Shoji, M., Golde, T.E., Ghiso, J., Cheung, T.T., Estus, S., Shaffer, L.M., Cai, X.D.,
McKay, D.M., Tintner, R., Frangione, B., et al., 1992. Production of the Alzheimer
amyloid beta protein by normal proteolytic processing. Science 258, 126e129.
Subaiea, G.M., Adwan, L.I., Ahmed, A.H., Stevens, K.E., Zawia, N.H., 2013. Short-term
treatment with tolfenamic acid improves cognitive functions in Alzheimer’s
disease mice. Neurobiol. Aging 34 (10), 2421e2430.
Tamagno, E., Guglielmotto, M., Monteleone, D., Vercelli, A., Tabaton, M., 2012.
Transcriptional and post-transcriptional regulation of beta-secretase. IUBMB
Life 64, 943e950.
Terry, R.D., Gonatas, N.K., Weiss, M., 1964. Ultrastructural studies in Alzheimer’s
Presenile dementia. Am. J. Pathol. 44, 269e297.
Tokola, R.A., Kangasniemi, P., Neuvonen, P.J., Tokola, O., 1984. Tolfenamic acid,
metoclopramide, caffeine and their combinations in the treatment of migraine
attacks. Cephalalgia 4, 253e263.
Tomlinson, B.E., 1982. Plaques, tangles and Alzheimer’s disease. Psychol. Med. 12,
449e459.
Urbanc, B., Cruz, L., Buldyrev, S.V., Havlin, S., Irizarry, M.C., Stanley, H.E., Hyman, B.T.,
1999. Dynamics of plaque formation in Alzheimer’s disease. Biophys. J. 76,
1330e1334.
White, L.D., Cory-Slechta, D.A., Gilbert, M.E., Tiffany-Castiglioni, E., Zawia, N.H.,
Virgolini, M., Rossi-George, A., Lasley, S.M., Qian, Y.C., Basha, M.R., 2007. New
and evolving concepts in the neurotoxicology of lead. Toxicol. Appl. Pharmacol.
225, 1e27.
Wu, J., Basha, M.R., Brock, B., Cox, D.P., Cardozo-Pelaez, F., McPherson, C.A., Harry, J.,
Rice, D.C., Maloney, B., Chen, D., Lahiri, D.K., Zawia, N.H., 2008. Alzheimer’s
disease (AD)-like pathology in aged monkeys after infantile exposure to envi-
ronmental metal lead (Pb): evidence for a developmental origin and environ-
mental link for AD. J. Neurosci. 28, 3e9.
Zawia, N.H., Basha, M.R., 2005. Environmental risk factors and the developmental
basis for Alzheimer’s disease. Rev. Neurosci. 16, 325e337.
Zawia, N.H., Lahiri, D.K., Cardozo-Pelaez, F., 2009. Epigenetics, oxidative stress, and
Alzheimer disease. Free Radic. Biol. Med. 46, 1241e1249.
